Proinsulin-reactive CD4+ T-cell receptor (PI-reactive CD4+ TCR)

Proinsulin-reactive CD4+ T-cell receptors (TCRs) are specialized immune receptors expressed on T-helper cells that specifically recognize proinsulin-derived peptides presented by Major Histocompatibility Complex (MHC) class II molecules, such as HLA-DR4 or HLA-DQ8 (Mannering et al., 2010, J. Exp. Med.). In Type 1 Diabetes (T1D), proinsulin is a primary autoantigen, and the activation of these CD4+ T cells is a critical early step in the autoimmune cascade leading to the destruction of insulin-producing pancreatic beta cells (Nakayama et al., 2005, Nature). These TCRs mediate the secretion of pro-inflammatory cytokines and provide essential help for the activation of cytotoxic CD8+ T cells and B cells (Pathiraja et al., 2015, Diabetes). Therapeutic targeting of these receptors or the cells expressing them aims to arrest the progression of T1D by inducing immune tolerance or selectively depleting the autoreactive population. Current pharmacological approaches include antigen-specific immunotherapies, such as proinsulin peptide vaccines (e.g., C19-A3), and monoclonal antibodies like Teplizumab that modulate T-cell signaling (Peakman, 2021, Diabetologia). Additionally, experimental agents like NNC0114-0005 are designed to specifically block the interaction between the TCR and the proinsulin-MHC II complex. Monitoring these cells using MHC-peptide tetramers serves as a vital biomarker for disease progression and therapeutic efficacy (Tree et al., 2010, J. Clin. Invest.). The ultimate goal of targeting these TCRs is to preserve residual beta-cell mass and maintain endogenous insulin production in patients at risk for or recently diagnosed with T1D.

Other names

Proinsulin-specific T-cell receptorPI-TCRProinsulin-peptide-MHC-II-specific TCRInsulin-reactive CD4+ T-cell receptor

Modulation of autoreactive T-cell activation and induction of antigen-specific immune tolerance.